Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $47.6250.

Several equities research analysts have recently commented on SION shares. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Finally, Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a report on Tuesday. They set a “market outperform” rating and a $63.00 price target for the company.

Insider Transactions at Sionna Therapeutics

In related news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the transaction, the insider owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc sold 33,356 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 382,368 shares of company stock valued at $15,898,607. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SION. GF Fund Management CO. LTD. purchased a new position in shares of Sionna Therapeutics in the 4th quarter valued at about $36,000. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics during the third quarter worth about $30,000. Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics during the fourth quarter worth about $58,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the second quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics in the fourth quarter valued at about $89,000.

Sionna Therapeutics Stock Up 3.4%

SION opened at $37.32 on Wednesday. Sionna Therapeutics has a 52 week low of $7.26 and a 52 week high of $45.00. The business has a 50 day moving average price of $40.12 and a two-hundred day moving average price of $34.77. The company has a market cap of $1.67 billion and a PE ratio of -7.66.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.